OTLK Outlook Therapeutics Inc

$OTLK I have a feeling we are all going to be in for a big surprise, with a better than expected event, such as a partnership or licensing deal, sales goals exceeded, meaningful restriction or enforcement against 503B compounded bevacizumab, etc, that quickly and dramatically re-rates the stock and share price. And I was the one who believed the FDR would result in a reversal of the CRL, which almost never happens. What I mean by that is the near impossible happened already, but the events I described above are not even close to near impossible. I put my money where my mouth is Buster 

$OTLK The launch cannot be that far off. My hope is we get some license deal at the same time. If this can burn through that 55 million share overhang with a good run because of those two things this would be golden. Plenty of cash and proof someone really believes in it.

$OTLK Absolutely insane! SLS has $138.3M in cash but still needs final Phase 3 REGAL results before a potential BLA. KOD has $125.9M in cash, no product revenue and hasn’t even filed its BLA for Zenkuda, planned for Q4 2026. KOD even targets the same retina market as $OTLK , while SLS operates in oncology, a completely different field. Yet both command multi-billion-dollar valuations based largely on future hopes. Meanwhile, $OTLK raised $51.1M in net proceeds from its August offering and already has an FDA-approved product, initial European sales and a US launch ahead. Yes, commercialization, reimbursement and funding remain challenges. But why is speculative pipeline potential worth billions for SLS and KOD, while OTLK’s approved product and commercial opportunity receive so little recognition? All three carry risks, but $OTLK is clearly further along the path to commercialization. This valuation gap is absolutely ridiculous, in my view 👀

$OTLK Very important for OTLK!!!!!!! EyePoint is not only claiming that LUCIA failed to meet its target. The company is prematurely ending the LUGANO and LUCIA clinical trials for wet age-related macular degeneration (wet AMD), without completing the second year of follow-up, and cutting approximately 53% of its workforce. The restructuring is expected to generate savings of approximately $30 million annually, a one-time severance cost of about $9 million, and the reallocation of the remaining resources to the DURAVYU program for diabetic macular edema (DME). So, while management states that it will "evaluate next steps" in the field of wet AMD, its actions speak louder than words: operationally, the wet AMD program has been suspended indefinitely. For OTLK, this is far more important than the statistical details of the trial.

$OTLK Put your money where your mouth is $JNJ and announce your buying us (and $SLS ) out Tuesday morning! Double dog dare you.

$OTLK bullish trend. I’m just curious how much the stock price will go up after their news launch, their target prices are $1.60, $5.03 and $10.5, but when it comes to bio anything is possible maybe to your wildest imagination stock price, let’s hope they won’t keep diluting these stocks and raised enough money for the launch …

$OTLK The AMD drug market is estimated at roughly $10B-$12B+ globally and growing, with North America representing the largest regional share. A single product, Eylea, generated an estimated $11.15 billion global market value in 2026 according to industry market reports covering Eylea-related sales and market activity.OTLK is not trying to replace Eylea or Vabysmo completely. Its opportunity is mainly in the massive off-label bevacizumab segment: Many retina specialists already use bevacizumab because it is much cheaper. LYTENAVA™ is the first FDA-approved ophthalmic bevacizumab formulation. If physicians switch from compounded bevacizumab to FDA-approved LYTENAVA, OTLK could capture meaningful revenue without needing dominant market share. Back-of-the-Envelope OTLK Scenarios If LYTENAVA captures: 1% of a ~$10B market → roughly $100M/year opportunity 2% → roughly $200M/year 5% → roughly $500M/year

$OTLK One thing is clear: LYTENAVA has a tremendous strategic opportunity to capture a significant share of a massive, established market. FDA approval has opened the door. Now everything depends on management's ability to execute: competitive pricing, insurance coverage, reimbursement, and commercial adoption. The opportunity is real. The size of the success will depend entirely on execution. Strong execution could completely transform Outlook Therapeutics' valuation. The next few months could be decisive. 🔥

$OTLK Patience, we are nearly there. Launch is around the corner and soon it will be all about sales. Dont worry about little daily drops (which mostly recover anyway by day's end) Stay bullish! Launch followed by sales numbers is key. This time next year we will be asking if we can leave $10 behind and shoot for $20.

$OTLK • May 19: Intraday low of $0.2150 • June 22: Intraday high of $1.88 • That is a move of roughly +775% in about 5 weeks. That was the result of the FDR win, which still carried the risk of another CRL This shows you how quickly it can move, so don’t let today’s share price bother you.

$OTLK — The story is shifting from FDA approval to commercial execution. ✅ LYTENAVA received FDA approval on July 24, 2026 — a major milestone. ✅ Permanent J-Code application submitted to CMS. ✅ Experienced commercial leadership in place, with Greg DiPasquale joining as Chief Commercial Officer. ✅ U.S. launch targeted before year-end 2026. The opportunity now comes down to execution: reimbursement, physician adoption and revenue growth in a large retina market. The next chapter could be very interesting. 👀 Bullish on the potential — watching the milestones closely.

$OTLK -Not every passenger survives the ride. -The real longs are still here. -Still standing. Still bullish.

$OTLK Artificially suppressed by MMs. It’s amazing how they can manipulate the SP down and hold it down for months. Weak hands are taking the hit.

$OTLK it’s insane that companies like SLS and KOD have a multi billion dollar valuation without having any approved assets, while we are sitting here at a bit over a 100m

$OTLK A $115 MILLION MARKET CAP IS ABSOLUTELY RIDICULOUS! Let's put this into perspective: ✅ FDA-approved LYTENAVA. ✅ First approved ophthalmic bevacizumab in the US. ✅ Targeting a multibillion-dollar market. ✅ US commercial launch approaching. ✅ Reimbursement progress underway. ✅ Potential for $500M+ in annual US sales by 2030. And the ENTIRE company is valued at just $115M? Yes, financing and execution risks remain, but this valuation seems completely disconnected from the commercial potential. The market is pricing in failure before the launch even begins. $OTLK — MASSIVELY UNDERVALUED IMO! 🚀

$OTLK 🔥 Choosing Greg DiPasquale as Chief Commercial Officer is a major strategic move! This is a man who helped drive EYLEA's commercial success at Regeneron and knows the retina market, its physicians, and its distribution channels from the inside. Outlook didn't just hire a commercial executive. They chose someone who knows exactly how the competition operates and how to compete against it. With LYTENAVA approaching its US launch, having this level of experience leading commercialization and market access could be a game changer. This is the kind of leadership you bring in when you're serious about taking market share. 🚀

$OTLK Some positive news has to come out at one point. As we get closer to the year end, the probability of a getting positive news is increasing. It cannot be all doom and gloom.

$OTLK Thanks to for finding this! Another important step for LYTENAVA: CVS Caremark has established a specific guideline with authorization criteria for wet AMD. Building momentum, step by step. Forward we go!

$OTLK Thanks to for doing a great job tracking the hiring process, or here's a summary of the hiring sequence In one sentence: first access and payers, then reimbursement-focused field reps, then the finance and quality structure, and now commercial, legal and medical leadership. It fits the company’s stated timeline: customer contact in Q4, product in channel before year-end, full team in January and the J-code in April. Side note: the FP&A posting includes modeling “M&A, licensing, and co-promote deals.” That’s common wording for the role, not an announcement, but worth noting.

$OTLK 2-3 days later, ie after 10/12/2026 when the lock-up period expires , something might be coming like for a SP pump to either sustain or dump at the end..if I may speculate. Attached: